

4. Overview of Subsidiaries and Associates

(As of March 31, 2025)

Company Name	Location	Share Capital		Description of Operations (*1)	Voting Rights (*2)	Relationship			Note	
						Concurrent workers		Business transactions		
						Concurrent directors	Concurrent employees			
(Consolidated Subsidiaries)										
		Unit = million								
Eisai R&D Management Co., Ltd.	Tokyo, Japan	17	JPY	Management of pharmaceutical R&D	100.00%	Present	Present	The Company commissions a part of management and other functions related to R&D		
Sunplanet Co., Ltd.	Tokyo, Japan	455	JPY	Business support services, etc.	100.00%	Present	Present	The Company purchases business support services, etc.		
EA Pharma Co., Ltd.	Tokyo, Japan	9,145	JPY	Pharmaceutical R&D / production / sales	60.00%	Present	Present	The Company commissions pharmaceutical R&D and production / purchases pharmaceutical products	*3	
Arteryx Inc.	Tokyo, Japan	108	JPY	Software planning and development	67.28%	Present	Present	The Company commissions system development		
Theoria technologies Co., Ltd.	Tokyo, Japan	350	JPY	Software planning and development	100.00%	Present	Present	The Company commissions system development		
		Unit = thousand								
Eisai Corporation of North America	New Jersey, USA	1,711,700	USD	Americas holding company	100.00%	Present	-	-	*3	
Eisai Inc.	New Jersey, USA	151,600	USD	Pharmaceutical R&D / production / sales	100.00% (100.00%)	Present	-	The Company commissions pharmaceutical R&D and production / sells pharmaceutical products and API	*3 *5	
Eisai Innovation, Inc.	Massachusetts, USA	1	USD	Management of pharmaceutical investment	100.00% (100.00%)	Present	Present	The Company commissions management of investment in the U.S. and Europe		
Eisai Ltd.	Ontario, Canada	30,000	CAD	Pharmaceutical sales	100.00% (100.00%)	Present	-	-		
Eisai China Holdings Ltd.	Jiangsu, China	664,465	RMB	Chinese headquarters / holding company	100.00% (100.00%)	Present	Present	-	*3	
Eisai China Inc.	Jiangsu, China	576,125	RMB	Pharmaceutical production / sales	100.00% (100.00%)	Present	Present	The Company sells pharmaceutical products and API	*3	

Company Name	Location	Share Capital		Description of Operations (*1)	Voting Rights (*2)	Relationship			Note
						Concurrent workers		Business transactions	
						Concurrent directors	Concurrent employees		
Eisai (Suzhou) Trading Co., Ltd.	Jiangsu, China	70,000	RMB	Pharmaceutical sales	100.00% (100.00%)	Present	Present	The Company sells pharmaceutical products	*3
Eisai (Liaoning) Pharmaceutic al Co., Ltd.	Liaoning, China	50,000	RMB	Pharmaceutical production / sales	100.00% (100.00%)	Present	Present	-	
Eisai Europe Ltd.	Hertfordshir e, UK	184,138	GBP	Europe headquarters / holding company, pharmaceutical sales	100.00%	Present	Present	The Company commissions management and administration of pharmaceutical business	*3
Eisai Ltd.	Hertfordshir e, UK	46,009	GBP	Pharmaceutical R&D / sales	100.00% (100.00%)	Present	Present	The Company commissions pharmaceutical R&D	*3
Eisai Manufacturin g Ltd.	Hertfordshir e, UK	38,807	GBP	Pharmaceutical R&D / production	100.00% (100.00%)	Present	-	The Company sells pharmaceutical products and API / is commissioned pharmaceutical R&D	*3
Eisai GmbH	Frankfurt, Germany	7,669	EUR	Pharmaceutical sales	100.00% (100.00%)	Present	-	-	
Eisai S.A.S.	Paris, France	19,500	EUR	Pharmaceutical sales	100.00% (100.00%)	-	-	-	
Eisai B.V.	Amsterdam, Netherlands	540	EUR	Pharmaceutical sales	100.00% (100.00%)	Present	-		
Eisai Farmacéutica S.A.	Madrid, Spain	4,000	EUR	Pharmaceutical sales	100.00% (100.00%)	Present	-		
Eisai S.r.l.	Milan, Italy	3,500	EUR	Pharmaceutical sales	100.00% (100.00%)	Present	-	-	
Eisai Pharma AG	Zurich, Switzerland	3,000	CHF	Pharmaceutical sales	100.00% (100.00%)	Present	-	-	
Eisai AB	Stockholm, Sweden	10,000	SEK	Pharmaceutical sales	100.00% (100.00%)	Present	-	-	
Eisai Farmacêutica , Unipessoal Lda.	Lisbon, Portugal	1,250	EUR	Pharmaceutical sales	100.00% (100.00%)	Present	-	-	
Eisai SA/NV	Brussels, Belgium	2,001	EUR	Pharmaceutical sales	100.00% (100.00%)	Present	-	-	
Eisai GesmbH	Vienna, Austria	2,000	EUR	Pharmaceutical sales	100.00% (100.00%)	Present	-	-	
Limited Liability Company Eisai	Moscow, Russia	4,000	RUB	Pharmaceutical sales	100.00% (100.00%)	Present	-	-	
Eisai Asia Regional Services Pte. Ltd.	Singapore	34,469	SGD	Asia holding company	100.00%	Present	Present	-	
Eisai (Singapore) Pte. Ltd.	Singapore	300	SGD	Pharmaceutical sales	100.00% (100.00%)	Present	Present	The Company sells pharmaceutical products	
Eisai Clinical Research Singapore Pte. Ltd.	Singapore	10	SGD	Pharmaceutical R&D	100.00% (100.00%)	Present	Present	The Company commissions pharmaceutical R&D	

Company Name	Location	Share Capital		Description of Operations (*1)	Voting Rights (*2)	Relationship			Note
						Concurrent workers		Business transactions	
						Concurrent directors	Concurrent employees		
Eisai Taiwan Inc.	Taipei, Taiwan	270,000	TWD	Pharmaceutical sales	100.00%	Present	Present	The Company sells pharmaceutical products	
Eisai (Thailand) Marketing Co., Ltd.	Bangkok, Thailand	103,000	THB	Pharmaceutical sales	100.00% (100.00%)	Present	Present	The Company sells pharmaceutical products	
PT Eisai Indonesia	Jakarta, Indonesia	1,630,000	IDR	Pharmaceutical production / sales	100.00%	Present	Present	The Company sells pharmaceutical products and API	
Eisai (Malaysia) Sdn. Bhd.	Petaling Jaya, Malaysia	470	MYR	Pharmaceutical sales	100.00% (5.74%)	Present	Present	The Company sells pharmaceutical products	
HI-Eisai Pharmaceutic al Inc.	Manila, Philippines	140,000	PHP	Pharmaceutical sales	50.00% (1.45%)	Present	Present	The Company sells pharmaceutical products	*4
Eisai (Hong Kong) Co., Ltd.	Hong Kong	500	HKD	Pharmaceutical sales	100.00% (10.00%)	Present	Present	The Company sells pharmaceutical products	
Eisai Korea Inc.	Seoul, South Korea	3,512,000	KRW	Pharmaceutical sales	100.00%	Present	Present	The Company sells pharmaceutical products	
Eisai Pharmaceutic als India Pvt. Ltd.	Andhra Pradesh, India	2,708,324	INR	Pharmaceutical R&D / production / sales	100.00% (11.08%)	Present	Present	The Company commissions pharmaceutical R&D and production / sells pharmaceutical products and API / purchases pharmaceutical products and API	*3
Eisai Australia Pty. Ltd.	Sydney, Australia	4,000	AUD	Pharmaceutical sales	100.00%	Present	-		
Eisai Laboratórios Ltda.	São Paulo, Brazil	87,899	BRL	Pharmaceutical sales	100.00% (100.00%)	-	-	-	
Eisai Laboratorios S. de R.L. de C.V.	Mexico City, Mexico	3	MXN	Pharmaceutical sales	100.00% (100.00%)	Present	Present	-	
Eisai New Zealand Ltd.	Auckland, New Zealand	2,050	NZD	Pharmaceutical sales	100.00% (100.00%)	Present	-	-	
Eisai Vietnam Co., Ltd.	Ho Chi Minh, Viet Nam	291,271,000	VND	Pharmaceutical sales	100.00%	Present	Present	The Company sells pharmaceutical products	
Eisai Israel Ltd.	Tel Aviv, Israel	5,000	ILS	Pharmaceutical sales	100.00% (100.00%)	Present	-	-	
Eisai Pharmaceutic als Africa (Pty) Ltd	Johannesburg, South Africa	76,500	ZAR	Pharmaceutical sales	100.00%	Present	Present	The Company sells pharmaceutical products	
Eisai Pharmaceutic als Single Person Limited Liability Company	Riyadh, Saudi Arabia	32,800	SAR	Pharmaceutical sales	100.00%	Present	-	-	*7
Other – 2 companies	-	-	-	-	-	-	-	-	

Company Name	Location	Share Capital		Description of Operations (*1)	Voting Rights (*2)	Relationship			Note
						Concurrent workers		Business transactions	
						Concurrent directors	Concurrent employees		
(Associated Companies Accounted for Using the Equity Method)									
		Unit = million							
Jingyi Weixiang (Shanghai) Health Industry Development Limited Company	Shanghai, China	42,005	RMB	Provision of medical services	49.00% (49.00%)	Present	Present	-	

Notes:

- *1. "Description of Operations" indicates the segment applicable to the respective entity.
*2. Voting rights (%): Figures in parentheses show percentage indirectly owned by the Company.
*3. Specified subsidiaries.
*4. HI-Eisai Pharmaceutical Inc. is considered to be a consolidated subsidiary as the Company holds effective control over its operation even though the Company's voting rights do not exceed 50%.
*5. Eisai Inc. is the only subsidiary whose revenue to external customers exceeds 10% of consolidated revenue reported in the consolidated financial statements for the fiscal year ended March 31, 2025. Key financial results (in Japanese yen) of Eisai Inc. are as follows:

Revenue	¥402,914 mil.
Operating Profit	¥(17,710) mil.
Profit for the year	¥(11,852) mil.
Total Equity	¥336,397 mil.
Total Assets	¥542,576 mil.

- *6. In April 2024, the Company absorbed and merged with KAN Research Institute, Inc. (Hyogo Prefecture, Japan).
*7. In April 2024, Eisai Europe Ltd. established Eisai Pharmaceuticals Single Person Limited Liability Company (in Saudi Arabia).
*8. In May 2025, the Company acquired EcoNaviSta Inc. (Tokyo) through a tender offer and made it a consolidated subsidiary.